Outpost Medicine pivots to 'new class of oral therapy' for IBS — 3 insights

After discontinuing a drug therapy program that "did not live up to its promise," Outpost Medicine shifted its focus towards OP-687, an oral therapy for overactive bladder and irritable bowel syndrome, IBJ reports.

Here's what you should know:

1. In a release, the company said its new therapy "holds great potential to significantly improve the care of patients with OAB and IBS, disorders that affect over one in 10 people worldwide."

2. Outpost also closed $20 million in funding, bringing its total funding to $61 million since its formation in March 2016.

3. Takeda, Frazier Healthcare Partners, Novo Holdings, Vivo Capital and Adam Street Partners all participated in the new funding round.

More articles on gastroenterology:
Physician fee schedule slashes GI anesthesia reimbursement — 5 insights
GI leader to know: Dr. John Vainder of Illinois Gastroenterology Group
Endoscopy a viable alternative to surgery for Barrett's esophagus patients — 3 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months